Osteosarcoma - Pipeline Review, H1 2017

Description: Osteosarcoma - Pipeline Review, H1 2017

Summary:

The latest Pharmaceutical and Healthcare disease pipeline guide Osteosarcoma - Pipeline Review, H1 2017, provides an overview of the Osteosarcoma (Oncology) pipeline landscape.

Osteosarcoma is the most common cancer of the bone that destroys tissue and weakens the bone. It is developed from immature bone cells that normally form new bone tissue. Symptoms include pain, bone fractures, swelling, redness and limitation of motion of joints. Risk factors include age, gender, family history and Li-Fraumeni syndrome. Treatment includes chemotherapy and surgery.

Report Highlights:

The latest Pharmaceutical and Healthcare latest pipeline guide Osteosarcoma - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Osteosarcoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Osteosarcoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Osteosarcoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 14, 7, 9 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 3, 3, 2 and 4 molecules, respectively.

Osteosarcoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from our proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

- The pipeline guide provides a snapshot of the global therapeutic landscape of Osteosarcoma (Oncology).
- The pipeline guide reviews pipeline therapeutics for Osteosarcoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Osteosarcoma (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Osteosarcoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Osteosarcoma (Oncology)
Reasons to Buy:

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Osteosarcoma (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Osteosarcoma (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents:

Introduction

Osteosarcoma - Overview

Osteosarcoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Osteosarcoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Osteosarcoma - Companies Involved in Therapeutics Development

Advaxis Inc

Allosteros Therapeutics Inc

Amgen Inc

AVEO Pharmaceuticals Inc

Bayer AG

Bellicum Pharmaceuticals Inc

Bristol-Myers Squibb Company

Celldex Therapeutics Inc
CorMedix Inc
CytRx Corp
Eisai Co Ltd
Eleison Pharmaceuticals LLC
Intezyne Technologies Inc
Isofol Medical AB
Johnson & Johnson
MacroGenics Inc
MD Biosciences GmbH
MediaPharma srl
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Novartis AG
Oncolys BioPharma Inc
Pfizer Inc
Shionogi & Co Ltd
Teijin Pharma Ltd
United Therapeutics Corp
Osteosarcoma - Drug Profiles
3D-QM - Drug Profile
3D-QMS - Drug Profile
ADXS-HER2 - Drug Profile
aldoxorubicin hydrochloride - Drug Profile
AM-7209 - Drug Profile
AU-101 - Drug Profile
AV-203 - Drug Profile
avelumab - Drug Profile
axitinib - Drug Profile
Cellular Immunotherapy for GD2 Expressing Solid Tumors - Drug Profile
Cellular Immunotherapy to Target HER2 for Glioblastoma Multiforme and Osteosarcoma - Drug Profile
Cellular Immunotherapy to Target MAGE-A1, MAGE-A3 and NY-ESO-1 for Oncology - Drug Profile

Celyvir - Drug Profile
cisplatin SR - Drug Profile
daunorubicin hydrochloride - Drug Profile
dihydroartemisinin - Drug Profile
dinutuximab - Drug Profile
enoblituzumab - Drug Profile
everolimus - Drug Profile
glembatumumab vedotin - Drug Profile
ipilimumab + nivolumab - Drug Profile
irinotecan hydrochloride - Drug Profile
IT-139 - Drug Profile
JNJ-64457107 - Drug Profile
lenvatinib mesylate - Drug Profile
ligerin - Drug Profile
MD-401A - Drug Profile
Modufolin - Drug Profile
Monoclonal Antibody for Osteosarcoma - Drug Profile
Monoclonal Antibody to Inhibit GD2 for Oncology - Drug Profile
Monoclonal Antibody to Target Ganglioside GD2 for Neuroblastoma and Osteosarcoma - Drug Profile
MPE-8.3 - Drug Profile
NT-157 - Drug Profile
OBP-702 - Drug Profile
Oligonucleotides to Inhibit Thymidylate Synthase and Dihydrofolate Reductase for Osteosarcoma and Colon Cancer - Drug Profile
pazopanib hydrochloride - Drug Profile
pembrolizumab - Drug Profile
Peptide to Target COX-2 and MAS-GPCR for Oncology - Drug Profile
radium Ra 223 dichloride - Drug Profile
RSF-101 - Drug Profile
S-588410 - Drug Profile
SEN-461 - Drug Profile
Osteosarcoma - Pipeline by Allosteros Therapeutics Inc, H1
Osteosarcoma - Pipeline by Amgen Inc, H1
Osteosarcoma - Pipeline by AVEO Pharmaceuticals Inc, H1
Osteosarcoma - Pipeline by Bayer AG, H1
Osteosarcoma - Pipeline by Bellicum Pharmaceuticals Inc, H1
Osteosarcoma - Pipeline by Bristol-Myers Squibb Company, H1
Osteosarcoma - Pipeline by Celldex Therapeutics Inc, H1
Osteosarcoma - Pipeline by CorMedix Inc, H1
Osteosarcoma - Pipeline by CytRx Corp, H1
Osteosarcoma - Pipeline by Eisai Co Ltd, H1
Osteosarcoma - Pipeline by Eleison Pharmaceuticals LLC, H1
Osteosarcoma - Pipeline by Intezyne Technologies Inc, H1
Osteosarcoma - Pipeline by Isofol Medical AB, H1
Osteosarcoma - Pipeline by Johnson & Johnson, H1
Osteosarcoma - Pipeline by MacroGenics Inc, H1
Osteosarcoma - Pipeline by MD Biosciences GmbH, H1
Osteosarcoma - Pipeline by MediaPharma srl, H1
Osteosarcoma - Pipeline by Merck & Co Inc, H1
Osteosarcoma - Pipeline by Merck KGaA, H1
Osteosarcoma - Pipeline by Merrimack Pharmaceuticals Inc, H1
Osteosarcoma - Pipeline by Novartis AG, H1
Osteosarcoma - Pipeline by Oncolys BioPharma Inc, H1
Osteosarcoma - Pipeline by Pfizer Inc, H1
Osteosarcoma - Pipeline by Shionogi & Co Ltd, H1
Osteosarcoma - Pipeline by Teijin Pharma Ltd, H1
Osteosarcoma - Pipeline by United Therapeutics Corp, H1
Osteosarcoma - Dormant Projects, H1
Osteosarcoma - Discontinued Products, H1

List of Figures:
Number of Products under Development for Osteosarcoma, H1
Number of Products under Development by Companies, H1
Number of Products under Development by Universities/Institutes, H1
Number of Products by Top 10 Targets, H1
Number of Products by Stage and Top 10 Targets, H1
Number of Products by Top 10 Mechanism of Actions, H1
Number of Products by Stage and Top 10 Mechanism of Actions, H1
Number of Products by Routes of Administration, H1
Number of Products by Stage and Routes of Administration, H1
Number of Products by Molecule Types, H1
Number of Products by Stage and Molecule Types, H

Ordering:

Order Online - [http://www.researchandmarkets.com/reports/4189125/](http://www.researchandmarkets.com/reports/4189125/)

Order by Fax - using the form below

Order by Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Osteosarcoma - Pipeline Review, H1 2017
Web Address: http://www.researchandmarkets.com/reports/4189125/
Office Code: SC

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Product Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF)</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Single User:</td>
<td></td>
<td>USD 2000</td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Site License:</td>
<td></td>
<td>USD 4000</td>
</tr>
<tr>
<td>Electronic (PDF)</td>
<td></td>
<td>USD 6000</td>
</tr>
<tr>
<td>Enterprisewide:</td>
<td></td>
<td>USD 6000</td>
</tr>
</tbody>
</table>

* The price quoted above is only valid for 30 days. Please submit your order within that time frame to avail of this price as all prices are subject to change.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: *
______________________________
Job Title:
______________________________
Organisation:
______________________________
Address:
______________________________
City:
______________________________
Postal / Zip Code:
______________________________
Country:
______________________________
Phone Number:
______________________________
Fax Number:
______________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card:  
You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check:  
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer:  
Please transfer funds to:

<table>
<thead>
<tr>
<th>Account number</th>
<th>833 130 83</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sort code</td>
<td>98-53-30</td>
</tr>
<tr>
<td>Swift code</td>
<td>ULSBIE2D</td>
</tr>
<tr>
<td>IBAN number</td>
<td>IE78ULSB98533083313083</td>
</tr>
<tr>
<td>Bank Address</td>
<td>Ulster Bank, 27-35 Main Street, Blackrock, Co. Dublin, Ireland.</td>
</tr>
</tbody>
</table>

If you have a Marketing Code please enter it below:

Marketing Code: ________________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:

(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World